Please wait a minute...
1Traditional Medicine Research  2019, Vol. 4 Issue (4): 205-212    DOI: 10.12032/TMR20190508119
Special Issue on Integrative Surgery     
Effects of Da-Cheng-Qi decoction on enteroparalysis and serum inflammatory cytokines in patients with severe acute pancreatitis
Xiao Wang1,*(), Guo-Hong Yang1, Chen-Xiao Wang1, Chun-Ying Li1, Min Guo1, Ming-Hao Liu1, Zhen-Jun Zeng1, Jun Ma2, Qin-Sheng Zhang3
1Department of Gastroenterology, First Affiliated Hospital of Henan Traditional Chinese Medicine University, Zhengzhou, Henan, China.
2Department of Gastroenterology, Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
3Department of Gastroenterology, Henan Provincial Hospital of Traditional Chinese Medicine, Zhengzhou, Henan, China.
Download: HTML     PDF(1083KB)
Export: BibTeX | EndNote (RIS)      

Highlights

This study demonstrated that Chinese herbal formula Da-Cheng-Qi decoction combined with the conventional treatment could effectively decrease the serum levels of CCL2, CRP, and IL-8, relieve enteroparalysis, and shorten the duration of hospitalization in patients with severe acute pancreatitis

Traditionality

Da-Cheng-Qi decoction (DCQD) is a famous Chinese herbal formula that includes Radix et Rhizoma Rhei (Dahuang), Cortex Magnoliae Officinalis (Houpu), Fructus Aurantii Immaturus (Zhishi), and Natrii Sulfas (Mangxiao). The original record about DCQD can be traced back to the 3rd Century A.D. According to the description in Shanghan Lun, an ancient book of Chinese medicine published in Han Dynasty of China, DCQD had the effect of purging accumulation and clearing heat from the stomach and intestine.

Abstract

Objective: The objective of this study was to investigate the effects of Da-Cheng-Qi decoction (DCQD) on enteroparalysis and levels of the serum inflammatory cytokines C-C motif chemokine ligand 2 (CCL2) and interleukin-8 (IL-8) in patients with severe acute pancreatitis (SAP). Methods: A total of 48 patients diagnosed with SAP who hospitalized in First Affiliated Hospital of Henan Traditional Chinese Medicine University from May 1, 2016 to May 30, 2018 were randomly assigned to the control or treatment groups. Patients in the control group (n = 22) received conventional treatment and those in the treatment group (n = 26) received conventional treatment as well as additional DCQD for 10 days. The duration of abdominal pain and distension, the time when bowel sounds returned to normal, changes in the levels of serum amylase, lipase, C-reactive protein (CRP), CCL2 and IL-8, as well as acute physiology and chronic health evaluation (APACHE) II scores of patients on days 1 and 10 were recorded and compared. Results: The duration of abdominal pain and distension, the time when bowel sounds returned to normal, the levels of blood amylase, lipase and CRP, and APACHE II scores of patients in the treatment group decreased significantly compared with those of patients in the control group. Though there were no statistical differences in serum CCL2 and IL-8 concentrations on day 1 between patients in these two groups, the levels of serum CCL2 and IL-8 in the treatment group were lower than those in the control group on day 10. Conclusion: DCQD may decrease the levels of CCL2, CRP, and IL-8 in patients with SAP, quickly relieve enteroparalysis, and shorten hospitalization duration.



Key wordsDa-Cheng-Qi decoction      Severe acute pancreatitis      CRP      CCL2      IL-8     
Published: 05 July 2019
Fund:  This work was supported by Research Grant from Henan Provincial Administration of Traditional Chinese Medicine (No.2016ZY2033), Funds for Creative Research Team of Henan Province, and Creative Research Team of Chinese medicine research of Henan Province.
Corresponding Authors: Xiao Wang   
E-mail: wangxiao1113@126.com
Cite this article:

Xiao Wang, Guo-Hong Yang, Chen-Xiao Wang, Chun-Ying Li, Min Guo, Ming-Hao Liu, Zhen-Jun Zeng, Jun Ma, Qin-Sheng Zhang. Effects of Da-Cheng-Qi decoction on enteroparalysis and serum inflammatory cytokines in patients with severe acute pancreatitis. 1Traditional Medicine Research, 2019, 4(4): 205-212. doi: 10.12032/TMR20190508119

URL:

https://www.tmrjournals.com/tmr/EN/10.12032/TMR20190508119

Baseline data Control group
(n = 22)
Treatment group
(n = 26)
P
values
Sex (M/F)
Age (year)
Pathogen [(n)%] Cholelithiasis
Alcoholism
Hyperlipidemia
Idiopathic
APACHE II score (mean ± SD)
Balthazar CT score (mean ± SD)
12/10
48.5 ± 9.2
9 (40.9)
6 (27.3)
5 (22.7)
2 (9.1)
10.3 ± 5.6
4.8 ± 1.3
14/12
49.4 ± 8.9
10 (38.5)
8 (30.8)
6 (23.1)
2 (7.7)
9.9 ± 5.2
4.7 ± 1.5
0.234
0.215
0.752
0.702
0.728
0.510
0.262
0.257
Table 1 Baseline data analysis
M/F, Male/female; SD, Standard deviation.
Clinical manifestation Control group
(n = 22)
Treatment group
(n = 26)
P
Abdominal pain
Abdominal distension
Bowel sounds return
5.45 ± 2.27
5.12 ± 2.41
5.15 ± 2.17
3.81 ± 1.94
3.79 ± 1.93
3.67 ± 1.86
0.026
0.031
0.042
Table 2 The days of abdominal pain, abdominal distension and bowel sounds return to normal
Figure 1 Effects of DCQD on APACHE II score and CRP level
DCQD, Da-Cheng-Qi decoction; APACHE II, Acute physiology and chronic health evaluation II; CRP, C-reactive protein.
Figure 2 Effects of DCQD on the levels of amylase and lipase
DCQD, Da-Cheng-Qi decoction.
Figure 3 Effects of DCQD on the levels of CCL2 and IL-8
CL2, C-C motif chemokine ligand 2; IL-8, Interleukin-8; DCQD, Da-Cheng-Qi decoction.
1.   Navarro S. Historical review of our knowledge of acute pancreatitis. Gastroenterol Hepatol2018, 41: 143.e1-143.e10.
2.   Shah AP, Mourad MM, Bramhall SR.Acute pancreatitis: current perspectives on diagnosis and management. J Inflamm Res 2018, 11: 77-85.
doi: 10.2147/JIR
3.   Schietroma M, Pessia B, Carlei F, et al. Intestinal permeability and systemic endotoxemia in patients with acute pancreatitis. Ann Ital Chir 2016, 87: 138-144.
4.   Jha RK, Ma Q, Sha H, et al. Emerging role of resveratrol in the treatment of severe acute pancreatitis. Front Biosci 2010, 2: 168-175.
5.   Xiong B, Zhang JF, Zhang XG. Research progress in the mechanism of severe acute pancreatitis complicated with intestinal dynamic disorders. Med Recapitulat2018, 24: 226-230. (Chinese)
6.   Sakorafas GH, Tsiotou AG.Etiology and pathogenesis of acute pancreatitis: current concepts. J Clin Gastroenterol 2000, 30: 343-356.
doi: 10.1097/00004836-200006000-00002
7.   Behfar S, Hassanshahi G, Nazari A, et al. A brief look at the role of monocyte chemoattractant protein-1 (CCL2) in the pathophysiology of psoriasis. Cytokine 2018, 110: 226-231.
doi: 10.1016/j.cyto.2017.12.010
8.   Leighton SP, Nerurkar L, Krishnadas R, et al. Chemokines in depression in health and in inflammatory illness: a systematic review and meta-analysis. Mol Psychiatry 2018, 23: 48-58.
doi: 10.1038/mp.2017.205
9.   Yoshimura T.The chemokine MCP-1 (CCL2) in the host interaction with cancer: a foe or ally? Cell Mol Immunol 2018, 15: 335-345.
doi: 10.1038/cmi.2017.135
10.   Siddiqui JA, Partridge NC.CCL2/Monocyte chemoattractant protein 1 and parathyroid hormone action on bone. Front Endocrinol 2017, 8: 49.
11.   Evans AC, Papachristou GI, Whitcomb DC.Obesity and the risk of severe acute pancreatitis. Minerva Gastroenterol Dietol 2010, 56: 169-179.
12.   Mandalia A, Wamsteker EJ, DiMagno M. Recent advances in understanding and managing acute pancreatitis. F1000 Research 2018, 7: 959.
doi: 10.12688/f1000research
13.   Jin W, Li QJ, Luo XQ, et al. Da-Cheng-Qi decoction combined with conventional treatment for treating postsurgical gastrointestinal dysfunction. Evid Based Complement Alternat Med 2017, 1987396.
14.   Zhao JL, Zhong CJ, He ZY, et al. Effect of da-cheng-qi decoction on pancreatitis- associated intestinal dysmotility in patients and in rat models. Evid Based Complement Alternat Med 2015, 895717.
15.   Zhao XL, Zhang YM, Li J, et al. Tissue pharmacology of Da-Cheng-Qi decoction in experimental acute pancreatitis in rats. Evid Based Complement Alternat Med 2015, 283175.
16.   Zhang YM, Ren HY, Zhao XL, et al. Pharmacokinetics and pharmacodynamics of Da-Cheng-Qi decoction in the liver of rats with severe acute pancreatitis. World J Gastroenterol 2017, 23: 1367-1374.
doi: 10.3748/wjg.v23.i8.1367
17.   Kun Wu. Yi Fang Kao, People's Health Publishing House, 2007.
18.   Banks PA, Bollen TL, Dervenis C, et al. Acute pancreatitis classification working group: classification of acute pancreatitis-2012: revision of the atlanta classification and definitions by international consensus. Gut 2013, 62: 102-111.
doi: 10.1136/gutjnl-2012-302779
19.   Greenberg JA, Hsu J, Bawazeer M, et al. Clinical practice guideline: management of acute pancreatitis. Can J Surg 2016, 59: 128-140.
doi: 10.1503/cjs
20.   Akinosoglou K, Gogos C.Immune-modulating therapy in acute pancreatitis: Fact or fiction. World J Gastroenterol 2014, 20: 15200-15215.
doi: 10.3748/wjg.v20.i41.15200
21.   Zerem E.Treatment of severe acute pancreatitis and its complications. World J Gastroenterol 2014, 20: 13879-13892.
doi: 10.3748/wjg.v20.i38.13879
22.   Manohar M, Verma AK, Venkateshaiah SU, et al. Pathogenic mechanisms of pancreatitis. World J Gastrointest Pharmacol Ther 2017, 8: 10-25.
doi: 10.4292/wjgpt.v8.i1.10
23.   Yang YZ, Xiang Y, Chen M, et al. Clinical significance of dynamic detection for serum levels of MCP-1, TNF-α and IL-8 in patients with acute pancreatitis. Asian Pac J Trop Med 2016, 9: 1111-1114.
doi: 10.1016/j.apjtm.2016.09.001
No related articles found!